Breaking News Instant updates and real-time market news.

CMD

Cantel Medical

, CNMD

CONMED

$60.02

-0.07 (-0.12%)

10:30
02/13/18
02/13
10:30
02/13/18
10:30

Needham a buyer of Medical Technologies product makers on Amazon headlines

After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).

CMD

Cantel Medical

CNMD

CONMED

$60.02

-0.07 (-0.12%)

MDT

Medtronic

$79.67

-0.57 (-0.71%)

TFX

Teleflex

$255.13

-0.075 (-0.03%)

ATRC

AtriCure

$15.52

0.21 (1.37%)

CSII

Cardiovascular Systems

$22.84

0.44 (1.96%)

HRC

Hill-Rom

$80.01

-1.03 (-1.27%)

KTWO

K2M Group

$18.51

-0.02 (-0.11%)

MZOR

Mazor Robotics

$61.30

1.59 (2.66%)

ZBH

Zimmer Biomet

$115.51

-1.01 (-0.87%)

BSX

Boston Scientific

$25.91

-0.275 (-1.05%)

GMED

Globus Medical

$44.48

-0.58 (-1.29%)

NUVA

NuVasive

$46.62

0.19 (0.41%)

WMGI

Wright Medical

$20.04

0.32 (1.62%)

AMZN

Amazon.com

$1,386.23

46.63 (3.48%)

  • 14

    Feb

  • 21

    Feb

  • 22

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 14

    Mar

  • 18

    Mar

  • 23

    Mar

CMD Cantel Medical

08/02/17
SIDC
08/02/17
UPGRADE
Target $92
SIDC
Buy
Cantel Medical upgraded to Buy from Neutral at Sidoti
Sidoti analyst Mitra Ramgopal upgraded Cantel Medical to Buy citing valuation and maintained its $92 price target.
06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
06/09/17
DOWNGRADE

Hold
Cantel Medical downgraded to Hold at Benchmark
As previously reported, Benchmark analyst Raymond Myers downgraded Cantel Medical to Hold from Buy, stating that he is increasingly concerned that its comparisons become tougher in the next two quarters. Myers, who expects the company's investments to drive its plan to double revenue and earnings to be front loaded, seeks more short-term clarity before recommending a Buy on the stock.
01/03/18
RAJA
01/03/18
UPGRADE
Target $115
RAJA
Outperform
Cantel Medical upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Lawrence Keusch upgraded Cantel Medical to Outperform from Market Perform and established a $115 price target. Keusch contents Cantel is a unique mid-cap growth story with a strong market position and earnings growth in the 13%-15% range. He expects robust earnings growth of 7%-9%, further accretive M&A, and income statement leverage beginning in FY19. The analyst has increased confidence Cantel can maintain its leadership position in the automated endoscope reprocessor market, which is a key growth driver due to competitor limitations.
CNMD CONMED
$60.02

-0.07 (-0.12%)

04/27/17
LEER
04/27/17
NO CHANGE
Target $52
LEER
Market Perform
CONMED price target raised to $52 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $52 from $45 after the company delivered a "good Q1" with revenue/EPS ahead of expectations. The analyst reiterates a Market Perform rating on the shares.
04/27/17
NEED
04/27/17
NO CHANGE
Target $54
NEED
Buy
CONMED price target raised to $54 from $48 at Needham
Needham analyst Mike Matson raised his price target for CONMED to $54 from $48 after the company's Q1 revenue and EPS beat consensus and management maintained its 2017 guidance. The analyst is encouraged by the improvement in revenue growth and reiterates a Buy rating, though he needs to see it sustained for a few more quarters before he is comfortable declaring the CONMED turnaround a success.
04/27/17
LTCO
04/27/17
DOWNGRADE
Target $47.5
LTCO
Neutral
CONMED downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen downgraded CONMED to Neutral from Buy as he sees "plenty of work ahead" for the company after its Q1 report showed only modest growth. He lowered his 2017 estimates and cut his price target on CONMED shares to $47.50 from $50.
02/01/18
NEED
02/01/18
NO CHANGE
Target $71
NEED
Buy
CONMED price target raised to $71 from $58 at Needham
Needham analyst Mike Matson raised his price target on CONMED to $71 and kept his Buy rating after Q4 earnings beat. The analyst says the company has "finally turned around its US Orthopedics business which was the one remaining drag on its growth". Matson also cites the management's forecast of sustaining mid-single digit revenue growth and double-digit EPS growth, which he adds may prove to be conservative.
MDT Medtronic
$79.67

-0.57 (-0.71%)

01/03/18
EVER
01/03/18
INITIATION
Target $92.5
EVER
Outperform
Medtronic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Medtronic with an Outperform rating and $92.50 price target. The analyst has confidence in the company's revenue growth accelerating in the second half of 2018. He finds the stock "compelling" at current share levels.
01/04/18
01/04/18
DOWNGRADE

Underperform
Dexcom to Underperform at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.
01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
02/12/18
OPCO
02/12/18
NO CHANGE
Target $67
OPCO
Outperform
Dexcom price target lowered to $67 from $72 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.
TFX Teleflex
$255.13

-0.075 (-0.03%)

11/03/17
NEED
11/03/17
NO CHANGE
Target $285
NEED
Buy
Teleflex price target raised to $285 from $237 at Needham
Needham analyst Mike Matson raised his price target on Teleflex to $285 and kept his Buy rating after Q3 results. Matson notes the 5% growth in revenue was up from 3.5% in the prior quarter, even though that was due to easier comps. The analyst also sees significant margin improvement in Q3 while forecasting accelerating revenue growth in Q4 reflecting sales of new products and the NeoTract and Vascular Solutions acquisitions.
11/14/17
DBAB
11/14/17
DOWNGRADE
Target $251
DBAB
Hold
Teleflex downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Kristen Stewart downgraded Teleflex to Hold with an unchanged price target of $251 citing valuation. The stock now fully reflects the improved fundamentals, particularly that with NeoTract, Stewart tells investors in a research note.
01/30/18
LEER
01/30/18
NO CHANGE
Target $321
LEER
Outperform
Teleflex price target raised to $321 from $307 at Leerink
Leerink analyst Richard Newitter raised his price target for Teleflex to $321 from $307 saying recent checks reinforce his view that the company can nearly double its organic sales growth profile by 2019 once Neotract/Urolift turns organic. With the step-up in growth that Neotract provides, the analyst believes Teleflex will be able to sustain 7%-8% top-line growth through 2020 while delivering 15%-20% EPS growth. Newitter reiterates an Outperform rating on the shares.
11/10/17
PIPR
11/10/17
INITIATION
Target $295
PIPR
Overweight
Teleflex assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of Teleflex with an Overweight rating and $295 price target. The analyst sees the NeoTract acquisition, along with continued operational improvements, driving "solid" revenue growth.
ATRC AtriCure
$15.52

0.21 (1.37%)

01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Overweight
AtriCure guidance possibly conservative, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted that the midpoint of AtriCure's 2018 revenue guidance is below the consensus estimate, but he believes management is being conservative, which he said they have been historically. The analyst, who remains confident in the stock's set up for 2018, would be buying shares today, he tells investors. O'Brien keeps an Overweight rating on AtriCure, which is up fractionally to $18.03 in afternoon trading.
12/10/17
PIPR
12/10/17
NO CHANGE
Target $24
PIPR
Overweight
Piper Jaffray remains bullish on AtriCure, sees potential acceleration in 2020
Piper Jaffray analyst Matt O'Brien notes that he hosted investor meeting with AtriCure's CFO Andy Wade. Looking longer-term, the analyst believes the results of the Converge trial and a sub-x Clip might result in accelerating growth starting in 2020, which he believes would push shares much higher. Consequently, O'Brien encourages investors to start or build positions in this "compelling franchise." He reiterates an Overweight rating and $24 price target on the shares.
11/02/17
PIPR
11/02/17
NO CHANGE
Target $24
PIPR
Overweight
AtriCure weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the post-earnings weakness in shares of AtriCure as a buying opportunity. The lowered sales outlook is largely the result of a spillover of deferrals from physician disruptions and fires in California, O'Brien tells investors in a post-earnings research note. The analyst views the headwinds as transitory and believes AtriCure can reaccelerate growth into 2018. He lowered his price target for the shares to $24 from $26 and maintains an Overweight rating on the name.
07/17/17
ADAM
07/17/17
NO CHANGE
ADAM
M&A in med-tech space will accelerate, says Canaccord
Canaccord analyst Jason Mills remains cautious in the med-tech space but believes M&A will continue to be a major theme. He noted the sector is trading at peak levels and recommends trading around core positions and looking for pullbacks to average down in favorite names. He said the most likely takeout names, in this order, are, Nevro (NVRO), AtriCure (ATRC), NxStage Medical (NXTM), iRhythm (IRTC), and Penumbra (PEN).
CSII Cardiovascular Systems
$22.84

0.44 (1.96%)

12/15/17
NEED
12/15/17
DOWNGRADE
NEED
Hold
Cardiovascular Systems cut to Hold at Needham on limited revenue potential
As reported earlier, Needham analyst Mike Matson downgraded Cardiovascular Systems (CSII) to Hold from Buy. Matson says he sees limited upside potential for FY18 consensus revenue and also notes a potential competitive threat from Boston Scientific's (BSX) new version of Rotablator expected in early 2018. The analyst contends that Cardiovascular Systems shares are fairly valued based on his revenue growth forecasts.
12/15/17
NEED
12/15/17
DOWNGRADE
NEED
Hold
Cardiovascular Systems downgraded to Hold from Buy at Needham
12/21/17
WBLR
12/21/17
INITIATION
WBLR
Market Perform
Cardiovascular Systems assumed with a Market Perform at William Blair
William Blair analyst Margaret Kaczor assumed coverage of Cardiovascular Systems with a Market Perform rating saying the company remains a "show-me story." Penetration of Cardiovascular's "compelling" technology, despite being on the market for over a decade, has only reached 9% of the orbital atherectomy market, Kaczor tells investors in a research note,
02/02/18
LSCM
02/02/18
NO CHANGE
Target $40
LSCM
Buy
Cardiovascular Systems selloff brings compelling entry point, says Lake Street
Lake Street analyst Brooks O'Neil believes the recent weakness in shares of Cardiovascular Systems offers investors a compelling entry point. The analyst expects the stock to stabilize now that the company has added "complementary products to its sales bag," hired a COO from Medtronic, and has begun to commercialize its Diamondback 360 Coronary OAS Micro Crown in Japan. O'Neil affirms a Buy rating on Cardiovascular Systems with a $40 price target.
HRC Hill-Rom
$80.01

-1.03 (-1.27%)

01/02/18
MSCO
01/02/18
DOWNGRADE
Target $95
MSCO
Equal Weight
Hill-Rom downgraded to Equal Weight on valuation at Morgan Stanley
As previously reported, Morgan Stanley analyst David Lewis downgraded Hill-Rom to Equal Weight from Overweight after the shares rose 50% in 2017. He continues to see a steady transformation into a more diversified, durable business and sees the company's FY18 revenue guidance as achievable, though he believes its transformation is increasingly reflected in consensus estimates. Lewis raised his price target on Hill-Rom shares to $95 from $90.
01/03/18
RAJA
01/03/18
UPGRADE
Target $94
RAJA
Outperform
Hill-Rom upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Lawrence Keusch upgraded Hill-Rom to Outperform from Market Perform and established a $94 price target. He expects accelerating revenue growth to 4%+ in FY18 up from 3% core growth in FY17, continued margin expansion opportunities, and potential upside from capital deployment. The analyst is confident the company can deliver revenue growth acceleration through new products and expects margin expansion more consistent with management's guidance.
01/16/18
NEED
01/16/18
NO CHANGE
Target $105
NEED
Buy
Hill-Rom price target raised to $105 from $90 at Needham
Needham analyst Mike Matson raised his price target on Hill-Rom to $105 after the company's above-consensus pre-announced Q1 results due to the positive impact of U.S. tax reform. Matson also cites the management's view of revenue upside across the company's businesses as well as the stock price trading at a 22% discount relative to small / mid-cap value peers' median FY18 PE, keeping his Buy rating on Hill-Rom.
01/02/18
MSCO
01/02/18
DOWNGRADE
MSCO
Equal Weight
Hill-Rom downgraded to Equal Weight from Overweight at Morgan Stanley
KTWO K2M Group
$18.51

-0.02 (-0.11%)

12/08/17
NEED
12/08/17
DOWNGRADE
Target $20
NEED
Buy
K2M Group downgraded to Buy at Needham on slower spine market
As reported earlier, Needham analyst Mike Matson downgraded K2M Group to Buy from Strong Buy and lowered his price target to $20 from $26. Matson says it is unclear when the slowing spine market will start to recover, adding that he no longer expects the company to produce "significant upside" to consensus estimates. The analyst notes that there is still a possibility that K2M is acquired given its strong product cycle.
12/28/17
PIPR
12/28/17
NO CHANGE
PIPR
Piper says own K2M, NuVasive into January conference
Piper Jaffray analyst Matt O'Brien recommends owning shares of K2M Group (KTWO) and NuVasive (NUVA) into a competitor conference that begins on January 8. The analyst is cautious on Zimmer Biomet (ZBH) into the conference. K2M and NuVasive are names to own going into the conference as both will meet or beat Q4 revenue estimates, O'Brien tells investors in a research note. He sees a favorable 2018 outlook for both companies as well as room for multiple expansion. On Zimmer, which the analyst downgraded recently, O'Brien continues to believe the company's turnaround will take longer than investors realize.
01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Overweight
Piper recommends buying K2M Group shares after pre-announcement
After K2M Group pre-announced preliminary Q4 revenue that beat consensus estimates and Piper Jaffray's forecast and also issued FY18 revenue guidance, analyst Matt O'Brien believes the newly-issued numbers are enough to bring investors back with increased confidence after the "angst" that preceded the company's outlook. The analyst, who notes that K2M continues outpacing market growth rates by taking share, reiterates an Overweight rating on the stock.
01/09/18
NEED
01/09/18
NO CHANGE
Target $23
NEED
Buy
K2M Group price target raised to $23 from $20 at Needham
Needham analyst Mike Matson raised his price target on K2M Group to $23 after the company's above-consensus Q4 guidance. Matson says outlook is likely to prove conservative in FY18 given the "easier comps, the sales organization transition, and a strong product cycle". The analyst keeps his Buy rating on K2M Group.
MZOR Mazor Robotics
$61.30

1.59 (2.66%)

10/30/17
LTCO
10/30/17
NO CHANGE
Target $67
LTCO
Buy
Mazor Robotics price target raised to $67 from $58 at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen raised his price target for Mazor Robotics to $67 after the company presented the first preliminary results from a prospective study of robotic-guided spine surgery at this year's North American Spine Society annual meeting. Various data and results to date are "remarkable and further validate the continued benefit for Mazor's technology," Cohen tells investors in a research note. The analyst reiterates a Buy rating on the shares.
10/19/17
LEHM
10/19/17
DOWNGRADE
Target $34
LEHM
Underweight
Mazor Robotics downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Matthew Taylor downgraded Mazor Robotics (MZOR) to Underweight with an unchanged price target of $34. The analyst believes the shares at current levels more than reflect the favorable feedback he heard during his firm's survey of 51 U.S. spine surgeons. Mazor has the best sentiment of any spine-related stock, Taylor adds, noting he can't justify the current valuation. On the other hand, the analyst sees greater than 20% upside for NuVasive (NUVA) over the next 12 months and views the recent selloff as overdone.
05/24/17
NEED
05/24/17
NO CHANGE
NEED
Hold
Medtronic unlikely to buy Mazor Robotics in near-term, says Needham
Needham analyst Mike Matson attributes some of the year-to-date advance in shares of Mazor Robotics (MZOR) to speculation that Medtronic (MDT) will acquire the company, though he sees that as unlikely in the near-term. Mazor shares are now trading "well above" the multiple that Stryker (SYK) paid to acquire Mako, noted Matson, who thinks its possible that Medtronic could eventually buy Mazor but only if the multiple declines via either a lower stock price or higher revenue. He keeps a Hold rating on Mazor shares.
08/30/17
LTCO
08/30/17
NO CHANGE
Target $54
LTCO
Buy
Mazor Robotics price target raised to $54 from $46 at Ladenburg
Ladenburg analyst Jeffrey Cohen noted that Mazor Robotics (MZOR) announced that it has entered the next phase of its strategic partnership with Medtronic (MDT) earlier than planned. He raised his price target on Mazor shares to $54 from $46, citing his valuation of the company's spine platform as well as his view of the value of its other market opportunities, and he keeps a Buy rating on the shares.
ZBH Zimmer Biomet
$115.51

-1.01 (-0.87%)

01/31/18
STFL
01/31/18
UPGRADE
STFL
Buy
Zimmer Biomet upgraded to Buy from Hold at Stifel
01/31/18
STFL
01/31/18
UPGRADE
Target $168
STFL
Buy
Stifel upgrades Zimmer Biomet to Buy on new CEO optimism
Stifel analyst Rick Wise upgraded Zimmer Biomet Holdings to Buy from Hold and raised his price target for the shares to $168 from $120. Under the new CEO, the analyst has greater conviction that the company can "gradually stabilize and, over time, re-accelerate growth." Wise cautious a turnaround will take time and that 2018-2020 estimates are likely to move lower. He believes, however, that this would represent a "clearing event," betting positioning Zimmer shares to outperform.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $142
RHCO
Buy
Zimmer Biomet price target raised to $142 from $127 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Zimmer Biomet to $142, citing his higher Hip & Knee sales forecasts, and favorable FX trends. The analyst also keeps his Buy rating, noting that he will monitor the progress toward remediation of quality issues, price and volume trends in the hip/knee markets, 2018 outlook for sales and earnings, and the growth prospects for the SET franchise.
01/29/18
MSCO
01/29/18
NO CHANGE
Target $150
MSCO
Overweight
Zimmer Biomet price target raised to $150 from $140 at Morgan Stanley
Morgan Stanley analyst David Lewis said he is not expecting Zimmer Biomet management to provide guidance beyond one quarter on its upcoming call and believes 2018 will largely be an investment year. However, he would expect Zimmer's profile to improve in the coming years as new CEO Bryan Hanson focuses on stabilization, then growth and asset optimization. Lewis raised his price target on Zimmer Biomet to $150 from $140), citing multiple expansion across large cap MedTech and his view on more normalized earnings in 2020.
BSX Boston Scientific
$25.91

-0.275 (-1.05%)

01/05/18
RBCM
01/05/18
UPGRADE
RBCM
Top Pick
Boston Scientific upgraded to Top Pick from Outperform at RBC Capital
01/05/18
RBCM
01/05/18
UPGRADE
Target $31
RBCM
Top Pick
Boston Scientific upgraded to Top Pick at RBC Capital
As reported earlier, RBC Capital analyst Glenn Novarro upgraded Boston Scientific to Top Pick from Outperform, keeping his $31 price target. Novarro says the Q4 earnings expected out on February 1st will be a positive catalyst in addressing concerns around 2018 outlook in late November when the company announced another delay in its LOTUS Edge system.
01/09/18
LEER
01/09/18
NO CHANGE
LEER
Outperform
Boston Scientific should outperform on 'strong beat,' says Leerink
Leerink analyst Danielle Antalffy notes that Boston Scientific preannounced better than expected Q4 results. The analyst sees this quarterly performance as particularly encouraging, given the fact that Boston Scientific delivered outperformance across all business segments despite facing a tough comp. Antalffy expects the stock to outperform on this strong beat, and continues to believe Boston Scientific represents "one of the most attractive" top-line growth stories in large-cap MedTech. She reiterates an Outperform rating on the shares.
01/03/18
EVER
01/03/18
INITIATION
Target $27
EVER
In Line
Boston Scientific initiated with an In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar started Boston Scientific with an In Line rating and $27 price target, stating that a lack of Lotus upside sets it up as a decelerating topline story.
GMED Globus Medical
$44.48

-0.58 (-1.29%)

01/10/18
WELS
01/10/18
NO CHANGE
Target $51
WELS
Outperform
Globus Medical price target raised to $51 from $46 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Globus Medical to $51 from $46 following the company's preliminary Q4 results and 2018 financial outlook, both of which exceeded expectations. The analyst reiterates an Outperform rating on the shares.
01/02/18
MSCO
01/02/18
UPGRADE
MSCO
Overweight
Globus Medical upgraded to Overweight from Equal Weight at Morgan Stanley
01/02/18
01/02/18
UPGRADE
Target $48

Overweight
Globus Medical upgraded to Overweight on undervalued robotics at Morgan Stanley
As previously reported, Morgan Stanley analyst Jonathan Demchick upgraded Globus Medical to Overweight from Equal Weight, stating that he thinks its robotics opportunity is being undervalued as he believes the consensus view appreciates the system opportunity, but is not adequately accounting for the impact from implant pull-through. Demchick raised his price target on Globus shares to $48 from $32.
01/05/18
WELS
01/05/18
NO CHANGE
WELS
Wells says buy Globus ahead of possible preannouncement next week
Wells Fargo analyst Larry Biegelsen recommends buying Globus Medical ahead of next week's likely preannouncement. The analyst expects placements of the company's new ExcelsiusGPS robot for spine to drive "strong" Q4 results. He keeps an Outperform rating on Globus Medical.
NUVA NuVasive
$46.62

0.19 (0.41%)

02/01/18
02/01/18
DOWNGRADE
Target $51

Market Perform
NuVasive downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Richard Newitter downgraded NuVasive to Market Perform from Outperform as he sees limited near-term upside to estimates. The analyst thinks any sustained increase in shares/multiple will be tough to come by without greater confidence that organic top-line growth can break out of low-single digit territory and management can more predictably under promise and over deliver on guidance as a result of new product launches or rising sales force productivity. The analyst also lowered his price target on the shares to $51 from $63.
02/01/18
LEER
02/01/18
DOWNGRADE
LEER
Market Perform
NuVasive downgraded to Market Perform from Outperform at Leerink
01/17/18
WELS
01/17/18
DOWNGRADE
Target $50
WELS
Market Perform
Wells Fargo sees headwinds for NuVasive, downgrades to Market Perform
Wells Fargo analyst Larry Biegelsen downgraded NuVasive to Market Perform from Outperform and lowered his price target for the shares to $50 from $65. The company's preliminary Q4 results suggest the guidance of mid-single digit growth in 2018 is too aggressive, Biegelsen tells investors in a research note. He believes NuVasive is "facing a number of headwinds," including a "weak" spine market; management departures in 2017 and "lukewarm" surgeon interest in its key new product, LessRay.
01/16/18
WELS
01/16/18
DOWNGRADE
WELS
Market Perform
NuVasive downgraded to Market Perform from Outperform at Wells Fargo
WMGI Wright Medical
$20.04

0.32 (1.62%)

01/04/18
CANT
01/04/18
INITIATION
Target $30
CANT
Overweight
Wright Medical assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Wright Medical with an Overweight rating and $30 price target.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
07/31/17
RBCM
07/31/17
NO CHANGE
RBCM
K2M Group, Wright Medical have 'favorable set-up' into results, says RBC Capital
RBC Capital analyst Glenn Novarro says that the decline of K2M (KTWO) and Wight Medical (WMGI) in sympathy with NuVasive (NUVA) has created a "favorable set-up" in the first two names heading into their Q2 results. The analyst says that in-line results by K2M and Wright Medical should lead to "relief rallies" by the stocks.
01/08/18
PIPR
01/08/18
NO CHANGE
Target $32
PIPR
Overweight
Piper recommends Wright Medical after preliminary Q4 results
Piper Jaffray analyst Matt O'Brien recommends investors purchase shares of Wright Medical following this morning's preliminary Q4 results. Wright reported preliminary Q4 revenue that beat consensus estimates, and importantly, 2017 sales came in at the high end of previously provided guidance range, O'Brien tells investors in a research note. The analyst sees a "solid set-up" for 2018 and keeps an Overweight rating on Wright Medical with a $32 price target.
AMZN Amazon.com
$1,386.23

46.63 (3.48%)

02/13/18
MACQ
02/13/18
NO CHANGE
Target $1750
MACQ
Outperform
Amazon's Twitch aggregate viewership continues to rise, says Macquarie
Macquarie analyst Benjamin Schachter says Amazon's (AMZN) Twitch aggregate viewership continues to rise, and Twitch is now bigger than CNN (TWX). While eSports as a whole is becoming a more concrete opportunity, the analyst notes that which games and genres will be the most popular/viewed eSports over time is unclear. Schachter also highlights that the Overwatch League launched to peak views of over 408K and over 10M unique viewers across the opening week, and that display ads on Amazon properties like Twitch are meaningful contributors to Other revenue, which grew 58% to $4.65B in 2017. He reiterates an Outperform rating and $1,750 price target on Amazon's shares.
02/13/18
WELS
02/13/18
NO CHANGE
WELS
AmerisourceBergen acquisition by Walgreens makes sense, says Wells Fargo
Commenting on The Wall Street Journal report saying Walgreens (WBA) has approached AmerisourceBergen (ABC) in a takeover attempt and the companies remain early in their discussions, Wells Fargo analyst Peter Costa tells investors he believes the acquisition makes sense given the already existing long-term partnership and limited ability to merge laterally. Further, the analyst believes a potential combination could help lower costs and wring out synergies in the U.S. drug distribution channel, and better position Walgreens in the face of increasing competitive threat from a possible Amazon (AMZN) entry. However, a merger might risk alienating AmerisourceBergen's retail pharmacy customers that compete with Walgreens' pharmacies, he contends.
02/13/18
DADA
02/13/18
NO CHANGE
Target $1800
DADA
Buy
Amazon.com investors should take advantage of pullback, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $1,800 on Amazon.com but says that investors should take advantage of the latest pullback to add to their positions. In addition to valuation, Forte cites the press reports on the latest hiring of Jennifer Salke as the new head of Amazon Studios, thereby filling "an important void after a potential period of disruption" and bringing one of its most significant areas of investment - proprietary content - back on track. The analyst notes that among Salke's prior accomplishments as the President of NBC Entertainment were hit shows such as "This Is Us", "Glee", "Modern Family", and "Prison Break".
02/12/18
BERN
02/12/18
NO CHANGE
BERN
'Ship with Amazon' gives options to merchants not storing with company, says Bernstein
Bernstein analyst David Vernon believes Amazon (AMZN) is trying to grow Fulfillment by Amazon volume without growing the FBA physical footprint. The "Ship with Amazon" feature seems like an attempt to make Amazon transportation options available to a select list of merchants who do not wish to pay Amazon for the cost of storing their inventory the fulfillment centers, he contends. The analyst believes UPS (UPS) and FedEx (FDX) need to enforce commercial discipline and communicate better.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.27

0.0027 (1.02%)

17:43
02/23/18
02/23
17:43
02/23/18
17:43
Hot Stocks
Gabriele Cerrone reports 7.0% stake in ContraVir Pharma, may seek board changes »

The shares of common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

17:41
02/23/18
02/23
17:41
02/23/18
17:41
Periodicals
VW settles U.S. diesel suit just before trial, Reuters reports »

Volkswagen's U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$153.99

3.2 (2.12%)

17:40
02/23/18
02/23
17:40
02/23/18
17:40
Hot Stocks
Breaking Hot Stocks news story on IAC »

Barry Diller reports 8.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SPG

Simon Property

$156.66

2.63 (1.71%)

17:37
02/23/18
02/23
17:37
02/23/18
17:37
Syndicate
Breaking Syndicate news story on Simon Property »

Simon Property files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$28.64

0.99 (3.58%)

17:35
02/23/18
02/23
17:35
02/23/18
17:35
Hot Stocks
Fabrinet director Frank Levinson buys 10,000 shares of company stock »

Frank Levinson, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 12

    Mar

  • 29

    Mar

CASI

Casi Pharmaceuticals

$3.85

0.1 (2.67%)

17:33
02/23/18
02/23
17:33
02/23/18
17:33
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

, TNDM

TNDM

17:31
02/23/18
02/23
17:31
02/23/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Dexcom, TNDM »

DexCom reports 5.6%…

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

TNDM

TNDM

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

IDXX

Idexx Laboratories

$187.61

3.75 (2.04%)

17:24
02/23/18
02/23
17:24
02/23/18
17:24
Hot Stocks
Idexx Laboratories director sells 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

CYDY

CytoDyn

$0.72

0.02 (2.86%)

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Syndicate
Breaking Syndicate news story on CytoDyn »

CytoDyn files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRUS

Merus

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Merus »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

MSG

Madison Square Garden

$231.97

2.41 (1.05%)

17:19
02/23/18
02/23
17:19
02/23/18
17:19
Hot Stocks
Silver Lake reports 4.9% stake in Madison Square Garden, may seek talks »

Silver Lake are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,121.90

14.9 (1.35%)

17:12
02/23/18
02/23
17:12
02/23/18
17:12
Syndicate
Breaking Syndicate news story on Markel »

Markel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

17:08
02/23/18
02/23
17:08
02/23/18
17:08
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$162.09

2.69 (1.69%)

, MYL

Mylan

$41.45

0.17 (0.41%)

17:04
02/23/18
02/23
17:04
02/23/18
17:04
Periodicals
PTAB denies Allergan's bid to dismiss restasis patent challenge, Bloomberg says »

Allergan's (AGN)…

AGN

Allergan

$162.09

2.69 (1.69%)

MYL

Mylan

$41.45

0.17 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 19

    Mar

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

SCHW

Charles Schwab

$52.74

0.71 (1.36%)

17:03
02/23/18
02/23
17:03
02/23/18
17:03
Hot Stocks
Charles Schwab appoints Joseph Martinetto as COO of the firm »

On February 22, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

, BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Kraft Heinz announces retirement of Warren Buffett from Board of Directors »

The Kraft Heinz Company…

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

BUD

AB InBev

$107.25

1.91 (1.81%)

QSR

Restaurant Brands

$59.46

1.02 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

SWX

Southwest Gas

$69.17

1.65 (2.44%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Southwest Gas increases quarterly common stock dividend »

The board for Southwest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MS

Morgan Stanley

$56.07

1.21 (2.21%)

, AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

16:56
02/23/18
02/23
16:56
02/23/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Applied Optoelectronics »

Morgan Stanley reports…

MS

Morgan Stanley

$56.07

1.21 (2.21%)

AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.